Literature DB >> 24559587

The predictive value of urinary UPIb mRNA levels in VUR and recurrent urinary tract infections.

Ipek Kaplan Bulut1, Sevgi Mir, Afig Berdeli, Betul Sozeri.   

Abstract

BACKGROUND: Vesicoureteral reflux (VUR) is a risk factor for progressive kidney damage especially when it is accompanied by urinary tract infections (UTIs). Uroplakins (UPs) are integral proteins found in the structure of urothelium. In the present study, we evaluated the usefulness of urinary UPIb messenger ribonucleic acid (mRNA) levels as an early and noninvasive diagnostic tool for VUR and as an indicator for predisposition to UTI.
METHODS: Urinary UPIb mRNA levels were determined in patients experiencing their first UTI episode (n = 28) or recurrent UTI (n = 31) as well as patients having UTI with VUR (n = 30). These results were compared to a control group (n = 26).
RESULTS: The UPIb mRNA values among patients diagnosed with their first UTI were lower, but not statistically different, than those in the control group. The UPIb mRNA levels of patients with recurrent UTI and UTI with VUR were significantly lower than those observed in control individuals.
CONCLUSION: Urine UPIb levels may be useful for predicting the risk of recurrent UTI in patients diagnosed with their first UTI and may also be considered as a noninvasive screening test for VUR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24559587     DOI: 10.5414/cn107778

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  2 in total

1.  Does the presence of vesicoureteral reflux affect in vitro uropathogenic E. coli growth rate in urine?

Authors:  Alper Soylu; Meral Karaman; Demet Alaygut; Seçil Arslansoyu Çamlar; Mehmet Türkmen; Salih Kavukçu
Journal:  Int Urol Nephrol       Date:  2015-12-17       Impact factor: 2.370

Review 2.  Tetraspanins as Potential Modulators of Glutamatergic Synaptic Function.

Authors:  Amina Becic; Jennifer Leifeld; Javeria Shaukat; Michael Hollmann
Journal:  Front Mol Neurosci       Date:  2022-01-03       Impact factor: 5.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.